For decades, doctors knew that certain individuals, particularly those of African ancestry with high-risk APOL1 gene variants, face dramatically elevated kidney disease risk. What they lacked were treatments designed specifically for this genetic risk. That is now changing rapidly.
The APOL1 Discovery
In 2010, researchers identified that two specific APOL1 variants, G1 and G2, were strongly associated with focal segmental glomerulosclerosis (FSGS), hypertension-associated CKD, and rapid progression to kidney failure in Black patients. This discovery opened an entirely new window for drug development.
What Clinical Trials Are Investigating
Several pharmaceutical companies are conducting Phase II and Phase III trials of APOL1-targeted therapies. These investigational drugs generally work by either reducing APOL1 protein production in kidney cells using RNA interference technology, or blocking the channel-forming activity believed to cause cellular damage.
Early results have been promising, some trials showing meaningful reductions in proteinuria and stabilization of eGFR compared to placebo.
Who May Be Eligible?
Most APOL1 trial protocols require participants to: – Be of African ancestry with confirmed high-risk variants – Have a diagnosis of APOL1-related nephropathy, FSGS, or hypertension-associated CKD – Have measurable proteinuria – Have eGFR within a specific range
What Participation Involves
Participants typically attend regular study visits for blood and urine testing, kidney function monitoring, and physician evaluation. All visits, testing, and study medications are provided at no cost.
If APOL1-targeted therapies succeed in clinical trials, the impact could be profound, potentially preventing hundreds of thousands of cases of kidney failure each year.